During the past decade, Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology" #1 sponsor was "Celgene" with 2 trials, followed by "Northwestern University" with 2 trials sponsored, "Chiron Corporation" with 1 trials sponsored, "Enzon Pharmaceuticals, Inc." with 1 trials sponsored and "Symphony Evolution, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Genzyme, a Sanofi Company" with 1 trials as a collaborator and "OSI Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology" are "AML" (1 trials), "Acute Myeloid Leukemia" (1 trials), "Adenocarcinoma" (1 trials), "Advanced Solid Tumors" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology" in a lesser frequency.

Most popular intervention types in "Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology" are "Drug" (7 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "5-fluorouracil" (1 trials), "Docetaxel and Prednisone" (1 trials), "EZN-2208" (1 trials), "Oral Azacitidine" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology" are 6 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".